Skip to Main Content

We have a new app!

Take the Access library with you wherever you go—easy access to books, videos, images, podcasts, personalized features, and more.

Download the Access App here: iOS and Android. Learn more here!

PITYRIASIS RUBRA PILARIS

Therapeutic Approach

Pityriasis rubra pilaris (PRP) is an inflammatory papulosquamous dermatosis of juvenile or adult onset. It is presenting with distinctive clinical features and a self-limiting or chronic evolution. The disease is subclassified into 6 types, including both hereditary and acquired forms. The hereditary form of PRP is linked to CARD14 gain-of-function mutations. The cause of the acquired forms I-IV is unknown. Type VI PRP is associated with HIV infection. Typical features are follicular hyperkeratotic papules that coalesce into scaly, reddish-orange–colored plaques. The disease may progress to erythroderma with well-demarcated islands of normal skin (“nappes claires”). Distinguishing PRP from psoriasis may pose a diagnostic challenge, particularly in early phases of the disease. Histopathologic examination reveals hyperkeratosis, alternating parakeratosis and orthokeratosis in a checkerboard pattern, with focal acantholytic dyskeratosis. The most successful treatment options are systemic retinoids, methotrexate as well as biologics; however, there is currently no FDA-approved therapy for PRP. Combining different systemic treatments or adjuvant photochemotherapy may be considered. See Table 7-1.

Table 7-1Pityriasis Rubra Pilaris Treatment Table

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.